Active Health
FACT

Antibiotic-based combination therapy fosmidomycin-artesunate-clindamycin for the concurrent treatment of severe malaria and bacterial blood stream infections in African children

€10.MFunding
60Months
10Partners

Fact sheet

Programme
Horizon Europe & sub-programmes
Companies
EURICE
Duration
60 months (September 2026 – August 2031)
Project funding
€ 10,139,216.25
Project partners
10
Project website
https://cordis.europa.eu/project/id/101248797

Project contact(s)

Your contact
Dr Silke von Sehlen
Senior Project Manager

About the project

Severe malaria is a major cause of preventable child mortality in sub-Saharan Africa. Around one third of children diagnosed with severe malaria may instead or additionally have a life-threatening bacterial bloodstream infection. Where rapid diagnostic differentiation is not possible, children may not receive both the antimalarial and antibacterial treatment they need.

FACT is developing a single parenteral combination therapy comprising artesunate, fosmidomycin and clindamycin. It is designed to treat severe malaria and important bacterial bloodstream infections simultaneously, also in the context of increasing artemisinin partial resistance and antimicrobial resistance.

The project will:

  • conduct a Phase II randomised dose-adjustment trial of parenteral FACT in African children with uncomplicated malaria;
  • conduct a pivotal multi-country Phase III trial evaluating efficacy, safety, tolerability and pharmacokinetics in African children with severe malaria;
  • assess resistance-associated mutations in Plasmodium isolates and antimicrobial resistance in bacterial bloodstream pathogens;
  • evaluate the cost-effectiveness and acceptability of FACT compared with the current standard of care; and
  • strengthen clinical-research capacity, with a particular focus on young African researchers and pharmacokinetic and PK/PD methods.

The clinical programme spans Gabon, the Republic of the Congo, Ghana and Ethiopia. Starting at TRL 6, FACT aims to reach TRL 8 and provide the evidence needed for subsequent treatment of severely ill children in malaria-endemic countries.

Coordinator

Dr Mirjam Groger
Bernhard-Nocht-Institut für Tropenmedizin (BNITM)
Email coordinator